Uniqure Stock Price, News & Analysis (NASDAQ:QURE)

$17.59 -0.93 (-5.02 %)
(As of 01/16/2018 10:52 AM ET)
Previous Close$18.52
Today's Range$17.57 - $18.58
52-Week Range$4.72 - $21.35
Volume508,000 shs
Average Volume440,967 shs
Market Capitalization$541.77 million
P/E Ratio-6.74
Dividend YieldN/A
Beta0.72

About Uniqure (NASDAQ:QURE)

Uniqure logoUniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships. The Company’s product candidates within the Core Program include AMT-061 for Hemophilia B, AMT-130 for Huntington's disease and S100A1 for congestive heart failure. The Company, through its collaboration with Bristol Myers-Squibb (BMS), is focused on building a portfolio of gene therapies led by the S100A1 program for congestive heart failure.

Receive QURE News and Ratings via Email

Sign-up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:QURE
CUSIPN/A
Phone+31-20-2406000

Debt

Debt-to-Equity Ratio0.73%
Current Ratio3.64%
Quick Ratio3.64%

Price-To-Earnings

Trailing P/E Ratio-6.73946360153257
Forward P/E Ratio-5.92
P/E GrowthN/A

Sales & Book Value

Annual Sales$25.10 million
Price / Sales21.58
Cash FlowN/A
Price / CashN/A
Book Value$2.53 per share
Price / Book6.95

Profitability

Trailing EPS($2.61)
Net Income$-73,370,000.00
Net Margins-338.39%
Return on Equity-170.28%
Return on Assets-40.50%

Miscellaneous

Employees251
Outstanding Shares30,800,000

Uniqure (NASDAQ:QURE) Frequently Asked Questions

What is Uniqure's stock symbol?

Uniqure trades on the NASDAQ under the ticker symbol "QURE."

How were Uniqure's earnings last quarter?

Uniqure NV (NASDAQ:QURE) posted its quarterly earnings results on Wednesday, November, 1st. The biotechnology company reported ($0.40) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.65) by $0.25. Uniqure had a negative net margin of 338.39% and a negative return on equity of 170.28%. View Uniqure's Earnings History.

When will Uniqure make its next earnings announcement?

Uniqure is scheduled to release their next quarterly earnings announcement on Wednesday, March, 21st 2018. View Earnings Estimates for Uniqure.

Where is Uniqure's stock going? Where will Uniqure's stock price be in 2018?

8 brokerages have issued twelve-month price objectives for Uniqure's stock. Their predictions range from $8.00 to $28.00. On average, they expect Uniqure's stock price to reach $19.86 in the next year. View Analyst Ratings for Uniqure.

What are Wall Street analysts saying about Uniqure stock?

Here are some recent quotes from research analysts about Uniqure stock:

  • 1. According to Zacks Investment Research, "UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. " (1/10/2018)
  • 2. Cowen Inc analysts commented, "QURE reported 1Q17 financials and presented multiple updates at ASGCT recently." (5/24/2017)

Who are some of Uniqure's key competitors?

Who owns Uniqure stock?

Uniqure's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FORESITE CAPITAL FUND II, L.P. (5.50%). Company insiders that own Uniqure stock include Christian Klemt, Harald Petry, Maria E Cantor and Matthew C Kapusta. View Institutional Ownership Trends for Uniqure.

How do I buy Uniqure stock?

Shares of Uniqure can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Uniqure's stock price today?

One share of Uniqure stock can currently be purchased for approximately $17.59.

How big of a company is Uniqure?

Uniqure has a market capitalization of $541.77 million and generates $25.10 million in revenue each year. The biotechnology company earns $-73,370,000.00 in net income (profit) each year or ($2.61) on an earnings per share basis. Uniqure employs 251 workers across the globe.

How can I contact Uniqure?

Uniqure's mailing address is Paasheuvelweg 25a, AMSTERDAM, 1105 BP, Netherlands. The biotechnology company can be reached via phone at +31-20-2406000 or via email at [email protected]


MarketBeat Community Rating for Uniqure (QURE)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  356 (Vote Outperform)
Underperform Votes:  132 (Vote Underperform)
Total Votes:  488
MarketBeat's community ratings are surveys of what our community members think about Uniqure and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Uniqure (NASDAQ:QURE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.712.712.75
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $19.86$19.00$13.25$16.57
Price Target Upside: 0.19% upside13.43% upside61.78% upside167.71% upside

Uniqure (NASDAQ:QURE) Consensus Price Target History

Price Target History for Uniqure (NASDAQ:QURE)

Uniqure (NASDAQ:QURE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/3/2018Janney Montgomery ScottInitiated CoverageBuy -> Buy$25.00LowView Rating Details
12/7/2017HC WainwrightSet Price TargetBuy$28.00HighView Rating Details
11/24/2017OppenheimerReiterated RatingHoldLowView Rating Details
11/7/2017Leerink SwannBoost Price Target$19.00 -> $26.00N/AView Rating Details
11/7/2017Evercore ISIInitiated CoverageOutperform -> Outperform$22.00N/AView Rating Details
7/23/2017Chardan CapitalSet Price TargetBuy$13.00HighView Rating Details
5/24/2017CowenReiterated RatingBuyMediumView Rating Details
4/12/2017Jefferies GroupReiterated RatingHold$8.00LowView Rating Details
12/6/2016WallachBeth CapitalLower Price TargetBuy$27.00 -> $15.00N/AView Rating Details
11/15/2016Piper Jaffray CompaniesDowngradeOverweight -> NeutralN/AView Rating Details
(Data available from 1/16/2016 forward)

Earnings

Uniqure (NASDAQ:QURE) Earnings History and Estimates Chart

Earnings by Quarter for Uniqure (NASDAQ:QURE)

Uniqure (NASDAQ QURE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/21/2018        
11/1/2017Q3 2017($0.65)($0.40)ViewN/AView Earnings Details
8/8/20176/30/2017($0.78)($0.83)$2.92 million$4.94 millionViewN/AView Earnings Details
5/9/20173/31/2017($0.64)($0.80)$4.20 million$3.32 millionViewN/AView Earnings Details
3/15/2017Q4 2016($0.52)($0.58)ViewN/AView Earnings Details
11/22/2016Q3 2016($0.86)($0.60)ViewN/AView Earnings Details
8/25/2016Q2 2016($0.87)($0.98)ViewN/AView Earnings Details
5/31/2016Q1($0.82)($0.93)$2.94 million$4.30 millionViewN/AView Earnings Details
4/4/2016Q415($0.60)($0.58)$2.78 million$6.78 millionViewN/AView Earnings Details
11/30/2015Q315($0.64)($1.14)$7.76 million$3.50 millionViewListenView Earnings Details
8/27/2015Q215($0.56)($0.98)$31.18 million$1.79 millionViewN/AView Earnings Details
6/11/2015Q1($0.82)($0.69)$9.50 million$1.17 millionViewN/AView Earnings Details
4/6/2015($0.62)($0.77)$1.38 million$1.61 millionViewN/AView Earnings Details
12/1/2014($0.53)($0.61)$2.00 million$1.30 millionViewN/AView Earnings Details
9/2/2014Q214($0.55)($1.35)$1.40 million$1.37 millionViewN/AView Earnings Details
6/6/2014($0.45)($0.52)$0.84 million$1.59 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Uniqure (NASDAQ:QURE) Earnings Estimates

2018 EPS Consensus Estimate: ($2.90)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.81)($0.81)($0.81)
Q2 20181($0.80)($0.80)($0.80)
Q3 20181($0.81)($0.81)($0.81)
Q4 20181($0.48)($0.48)($0.48)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Uniqure (NASDAQ:QURE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Uniqure (NASDAQ QURE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.73%
Institutional Ownership Percentage: 24.87%
Insider Trades by Quarter for Uniqure (NASDAQ:QURE)
Institutional Ownership by Quarter for Uniqure (NASDAQ:QURE)

Uniqure (NASDAQ QURE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/4/2018Matthew C. KapustaCEOSell21,690$19.87$430,980.30View SEC Filing  
1/3/2018Christian KlemtInsiderSell5,093$20.13$102,522.09View SEC Filing  
1/3/2018Maria E. CantorSVPSell5,864$20.13$118,042.32View SEC Filing  
6/29/2017Harald PetryInsiderSell49,300$6.02$296,786.0027,753View SEC Filing  
6/27/2017Harald PetryInsiderSell65,930$6.01$396,239.30155View SEC Filing  
6/26/2017Harald PetryInsiderSell58,075$6.01$349,030.75155View SEC Filing  
6/22/2017Harald PetryInsiderSell155$6.00$930.00155View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Uniqure (NASDAQ QURE) News Headlines

Source:
DateHeadline
uniQure Provides Year-End 2017 Corporate Update and Outlines Near-Term Objectives to Further Drive Shareholder ValueuniQure Provides Year-End 2017 Corporate Update and Outlines Near-Term Objectives to Further Drive Shareholder Value
finance.yahoo.com - January 8 at 8:37 AM
Uniqure NV (QURE) Insider Christian Klemt Sells 5,093 SharesUniqure NV (QURE) Insider Christian Klemt Sells 5,093 Shares
www.americanbankingnews.com - January 5 at 6:50 PM
Matthew C. Kapusta Sells 21,690 Shares of Uniqure NV (QURE) StockMatthew C. Kapusta Sells 21,690 Shares of Uniqure NV (QURE) Stock
www.americanbankingnews.com - January 5 at 6:32 PM
Uniqure NV (QURE) SVP Sells $118,042.32 in StockUniqure NV (QURE) SVP Sells $118,042.32 in Stock
www.americanbankingnews.com - January 3 at 7:28 PM
Uniqure (QURE) Earns Buy Rating from Analysts at Janney Montgomery ScottUniqure (QURE) Earns Buy Rating from Analysts at Janney Montgomery Scott
www.americanbankingnews.com - January 3 at 6:24 PM
Uniqure (QURE) Lifted to Hold at ValuEngineUniqure (QURE) Lifted to Hold at ValuEngine
www.americanbankingnews.com - January 1 at 6:20 AM
Uniqure (QURE) Rating Increased to Hold at ValuEngineUniqure (QURE) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - December 29 at 10:10 PM
3 Reasons Spark Therapeutics Is a Buy After Its Crash3 Reasons Spark Therapeutics Is a Buy After Its Crash
finance.yahoo.com - December 28 at 4:26 PM
Uniqure (QURE) Stock Rating Upgraded by BidaskClubUniqure (QURE) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - December 28 at 2:38 PM
Uniqure NV (QURE) Given Average Recommendation of "Hold" by BrokeragesUniqure NV (QURE) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - December 22 at 4:12 PM
uniQure (QURE) Reports Publication of Clinical Data from Phase I/II Trial of AMT-060 In Patients with Severe ... - StreetInsider.comuniQure (QURE) Reports Publication of Clinical Data from Phase I/II Trial of AMT-060 In Patients with Severe ... - StreetInsider.com
www.streetinsider.com - December 18 at 3:39 PM
uniQure Announces Publication in the Journal Blood of Clinical Data from Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia BuniQure Announces Publication in the Journal Blood of Clinical Data from Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B
finance.yahoo.com - December 18 at 11:54 AM
uniQure: Continued Upside In 2018 - Seeking AlphauniQure: Continued Upside In 2018 - Seeking Alpha
seekingalpha.com - December 16 at 3:38 PM
Stock Traders Purchase High Volume of Call Options on Uniqure (QURE)Stock Traders Purchase High Volume of Call Options on Uniqure (QURE)
www.americanbankingnews.com - December 14 at 4:38 AM
7 Winners and Losers From Biggest Biotech Conference of 2017 - TheStreet.com7 Winners and Losers From Biggest Biotech Conference of 2017 - TheStreet.com
www.thestreet.com - December 13 at 3:42 PM
uniQure Added to NASDAQ Biotechnology IndexuniQure Added to NASDAQ Biotechnology Index
finance.yahoo.com - December 12 at 12:02 PM
BRIEF-UniQure Announces Updated, Long-Term Clinical Data From Ongoing Phase I/II Trial Of AMT-060 In Patients With Severe Hemophilia BBRIEF-UniQure Announces Updated, Long-Term Clinical Data From Ongoing Phase I/II Trial Of AMT-060 In Patients With Severe Hemophilia B
www.reuters.com - December 11 at 12:03 PM
UniQure shares jump 3.8% premarket on positive trial of hemophelia treatmentUniQure shares jump 3.8% premarket on positive trial of hemophelia treatment
finance.yahoo.com - December 11 at 12:03 PM
uniQure Announces Presentation of Non-Clinical Data of AMT-061 at the 59th American Society of Hematology (ASH ... - GlobeNewswire (press release)uniQure Announces Presentation of Non-Clinical Data of AMT-061 at the 59th American Society of Hematology (ASH ... - GlobeNewswire (press release)
globenewswire.com - December 9 at 11:18 AM
uniQure Announces Presentation of Non-Clinical Data of AMT-061 at the 59th American Society of Hematology (ASH) Annual MeetinguniQure Announces Presentation of Non-Clinical Data of AMT-061 at the 59th American Society of Hematology (ASH) Annual Meeting
finance.yahoo.com - December 9 at 11:18 AM
uniQure (QURE) Rating Reiterated by HC WainwrightuniQure (QURE) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - December 7 at 12:42 PM
uniQure (QURE) Stock Rating Lowered by ValuEngineuniQure (QURE) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - December 2 at 7:44 PM
uniQure (QURE) Coverage Initiated by Analysts at HC WainwrightuniQure (QURE) Coverage Initiated by Analysts at HC Wainwright
www.americanbankingnews.com - December 1 at 8:04 AM
uniQure N.V. (QURE) Given Consensus Rating of "Hold" by BrokeragesuniQure N.V. (QURE) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 27 at 4:26 PM
uniQures (QURE) "Hold" Rating Reiterated at Oppenheimer Holdings, Inc.uniQure's (QURE) "Hold" Rating Reiterated at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - November 27 at 1:14 PM
Traders Buy High Volume of uniQure N.V. Call Options (QURE)Traders Buy High Volume of uniQure N.V. Call Options (QURE)
www.americanbankingnews.com - November 25 at 2:28 AM
uniQure N.V. (QURE) Downgraded by Zacks Investment ResearchuniQure N.V. (QURE) Downgraded by Zacks Investment Research
www.americanbankingnews.com - November 12 at 7:48 PM
Leerink Swann Research Analysts Increase Earnings Estimates for uniQure N.V. (QURE)Leerink Swann Research Analysts Increase Earnings Estimates for uniQure N.V. (QURE)
www.americanbankingnews.com - November 9 at 7:21 AM
uniQure N.V. (QURE) vs. The Competition Critical ComparisonuniQure N.V. (QURE) vs. The Competition Critical Comparison
www.americanbankingnews.com - November 8 at 3:10 AM
uniQure N.V. (QURE) Price Target Raised to $26.00uniQure N.V. (QURE) Price Target Raised to $26.00
www.americanbankingnews.com - November 7 at 7:08 PM
uniQure NV :QURE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017uniQure NV :QURE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
finance.yahoo.com - November 7 at 9:22 AM
uniQure N.V. (QURE) Receives Consensus Rating of "Hold" from BrokeragesuniQure N.V. (QURE) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 2 at 5:46 PM
uniQure Announces Presentations at the 59th American Society of Hematology (ASH) Annual MeetinguniQure Announces Presentations at the 59th American Society of Hematology (ASH) Annual Meeting
finance.yahoo.com - November 2 at 8:13 AM
uniQure Announces Multiple Company Presentations at Upcoming November ConferencesuniQure Announces Multiple Company Presentations at Upcoming November Conferences
finance.yahoo.com - November 1 at 7:58 AM
uniQure Announces Third Quarter 2017 Financial Results and Recent Company ProgressuniQure Announces Third Quarter 2017 Financial Results and Recent Company Progress
finance.yahoo.com - November 1 at 7:57 AM
UniQure reports 3Q lossUniQure reports 3Q loss
finance.yahoo.com - November 1 at 7:57 AM
First Week of December 15th Options Trading For uniQure (QURE)First Week of December 15th Options Trading For uniQure (QURE)
www.thestreet.com - October 28 at 4:07 PM
uniQure Announces Closing of its Public OfferinguniQure Announces Closing of its Public Offering
finance.yahoo.com - October 28 at 4:07 PM
uniQure announces pricing of its 5M public offering - Seeking AlphauniQure announces pricing of its 5M public offering - Seeking Alpha
seekingalpha.com - October 27 at 12:58 PM
uniQure N.V.: uniQure Announces Pricing of its Public OfferinguniQure N.V.: uniQure Announces Pricing of its Public Offering
www.finanznachrichten.de - October 25 at 9:39 AM
uniQure Announces Pricing of its Public OfferinguniQure Announces Pricing of its Public Offering
finance.yahoo.com - October 25 at 9:39 AM
uniQure Announces Proposed Public OfferinguniQure Announces Proposed Public Offering
finance.yahoo.com - October 24 at 9:04 AM
UniQure Reaches Analyst Target PriceUniQure Reaches Analyst Target Price
www.thestreet.com - October 22 at 6:09 AM
Wall Streets M&A Chatter From October 19: Uniqure, Ulta, Sally Beauty, Tribune -Sinclair - BenzingaWall Street's M&A Chatter From October 19: Uniqure, Ulta, Sally Beauty, Tribune -Sinclair - Benzinga
www.benzinga.com - October 21 at 8:32 AM
Why uniQure NV Stock Is Hopping Today - Motley FoolWhy uniQure NV Stock Is Hopping Today - Motley Fool
www.fool.com - October 21 at 8:32 AM
uniQure N.V. (QURE) PT Raised to $19.00 at Leerink SwannuniQure N.V. (QURE) PT Raised to $19.00 at Leerink Swann
www.americanbankingnews.com - October 20 at 10:52 PM
Why uniQure N.V. Stock Is Hopping TodayWhy uniQure N.V. Stock Is Hopping Today
www.fool.com - October 20 at 4:09 PM
$2.00 Million in Sales Expected for uniQure N.V. (QURE) This Quarter$2.00 Million in Sales Expected for uniQure N.V. (QURE) This Quarter
www.americanbankingnews.com - October 20 at 5:16 AM
uniQure (QURE) Reports Hemophilia B Gene Therapy Program To Enter Pivotal Study With FIX-Padua Variant in 2018uniQure (QURE) Reports Hemophilia B Gene Therapy Program To Enter Pivotal Study With FIX-Padua Variant in 2018
www.streetinsider.com - October 19 at 8:28 PM
uniQure (QURE) Presents On Advancing AMT-061 in Hemophilia B - SlideshowuniQure (QURE) Presents On Advancing AMT-061 in Hemophilia B - Slideshow
seekingalpha.com - October 19 at 8:28 PM

SEC Filings

Uniqure (NASDAQ:QURE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Uniqure (NASDAQ:QURE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Uniqure (NASDAQ QURE) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.